2.4.1. Although it is not harmful to increase this quantity of glycerol, however the final formulation should not become too thick to process. 2.4.2. If this quantity is decreased, then for the relative increase in the quantity of water, it should be noted that the Tamoxifen Citrate would still dissolve considerably. 2.5. Hence, It is recommended that the glycol component should consist of about 10% by weight of propylene glycol and about 40% to 50% by weight of glycerol, in order to ensure the stability of Tamoxifen. 2.3. Research also suggests that for the formulation of Tamoxifen at highest stability so that the suspension of a fairly high percentage of Tamoxifen Citrate is made possible and simplicity of processing is maintained, the most favored formulation is a solvent mixture that consists of 15% by weight of ethanol, 10% by weight of propylene glycol, 50% by weight of glycerol, and 20% by weight of a sorbitol solution. The rest is the water. Such a formulation is stable enough to present a physically and chemically stable solution of Tamoxifen Citrate possessing the required amount of absorption. 3. Stability of Tamoxifen till its Release to the Market 3.1. To ensure the stability of Tamoxifen till its release to the market, the concept of nanoencapsulation has been implemented in the course of its strong ultrasonication and concurrent chronological polyelectrolyte deposition. 3.1.1. This is a fresh advancement that changes the thickness of the wall of the capsule so that the drug
release rate is adjusted and an antibody “at the outer shell layer for targeted delivery” is attached (Ochre Media 2010). 3.2. Another efficient method is to produce stable nanocolloids of Tamoxifen capsules which should have high substance of...
The Stability of Tamoxifen
There are two polymorphic forms of Tamoxifen’s crystals. The compound that is available normally is found as the meta stable polymorph. When Tamoxifen is crystalized from protic solvents, it starts forming crystals of the stable polymorph which shows disagreeable properties which results in yet additional insolubility of Tamoxifen in water. Thus, it remains stable. These detrimental properties of Tamoxifen influence its absorption performance in vivo which causes a reduction in its bioavailability. Tamoxifen’s polymorphic forms prevent the formulation of Tamoxifen Citrate as a suspension thus maintaining its stability during formulation. Because of the low intrinsic solubility of Tamoxifen’s molecule, even a little quantity that penetrates the aqueous solution leaves it soon enough, forming crystals of the unwanted polymorphic form. Hence, this level of stability of Tamoxifen during its formulation leads to the necessity of a “liquid formulation of Tamoxifen Citrate where crystallisation will not occur”.
After the primary polycation layer is deposited on the nanoparticle, an oppositely charged polyanion is added to it which forms a stable inter-polyelectrolyte complex shell around every drug nanoparticle. The final outermost layer is that of a polymer containing reactive groups like amino groups. It attaches ligands and desirable moieties to the surface of drug nanoparticles. This is how the Tamoxifen is stabilized till its release to the market.